JP2022513043A5 - - Google Patents

Info

Publication number
JP2022513043A5
JP2022513043A5 JP2021526460A JP2021526460A JP2022513043A5 JP 2022513043 A5 JP2022513043 A5 JP 2022513043A5 JP 2021526460 A JP2021526460 A JP 2021526460A JP 2021526460 A JP2021526460 A JP 2021526460A JP 2022513043 A5 JP2022513043 A5 JP 2022513043A5
Authority
JP
Japan
Prior art keywords
antibody
independently selected
reference target
manipulated
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021526460A
Other languages
English (en)
Japanese (ja)
Other versions
JP7695881B2 (ja
JP2022513043A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/061567 external-priority patent/WO2020102603A1/en
Publication of JP2022513043A publication Critical patent/JP2022513043A/ja
Publication of JP2022513043A5 publication Critical patent/JP2022513043A5/ja
Priority to JP2024199831A priority Critical patent/JP2025026923A/ja
Application granted granted Critical
Publication of JP7695881B2 publication Critical patent/JP7695881B2/ja
Priority to JP2026003911A priority patent/JP2026065087A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021526460A 2018-11-14 2019-11-14 操作されたｃｄ２５ポリペプチドおよびその使用 Active JP7695881B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024199831A JP2025026923A (ja) 2018-11-14 2024-11-15 操作されたｃｄ２５ポリペプチドおよびその使用
JP2026003911A JP2026065087A (ja) 2018-11-14 2026-01-13 操作されたｃｄ２５ポリペプチドおよびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862767431P 2018-11-14 2018-11-14
US62/767,431 2018-11-14
US201962902334P 2019-09-18 2019-09-18
US62/902,334 2019-09-18
PCT/US2019/061567 WO2020102603A1 (en) 2018-11-14 2019-11-14 Engineered cd25 polypeptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024199831A Division JP2025026923A (ja) 2018-11-14 2024-11-15 操作されたｃｄ２５ポリペプチドおよびその使用

Publications (3)

Publication Number Publication Date
JP2022513043A JP2022513043A (ja) 2022-02-07
JP2022513043A5 true JP2022513043A5 (https=) 2023-06-14
JP7695881B2 JP7695881B2 (ja) 2025-06-19

Family

ID=70731914

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021526460A Active JP7695881B2 (ja) 2018-11-14 2019-11-14 操作されたｃｄ２５ポリペプチドおよびその使用
JP2024199831A Pending JP2025026923A (ja) 2018-11-14 2024-11-15 操作されたｃｄ２５ポリペプチドおよびその使用
JP2026003911A Pending JP2026065087A (ja) 2018-11-14 2026-01-13 操作されたｃｄ２５ポリペプチドおよびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024199831A Pending JP2025026923A (ja) 2018-11-14 2024-11-15 操作されたｃｄ２５ポリペプチドおよびその使用
JP2026003911A Pending JP2026065087A (ja) 2018-11-14 2026-01-13 操作されたｃｄ２５ポリペプチドおよびその使用

Country Status (6)

Country Link
US (1) US12441803B2 (https=)
EP (1) EP3880698A4 (https=)
JP (3) JP7695881B2 (https=)
CN (1) CN113646330A (https=)
CA (1) CA3120102A1 (https=)
WO (1) WO2020102603A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109053882B (zh) * 2018-08-28 2019-08-23 东莞市朋志生物科技有限公司 一种ns1蛋白的结合蛋白以及应用
EP3880227A4 (en) 2018-11-14 2022-11-09 RubrYc Therapeutics, Inc. ANTI-CD25 ANTIBODIES
JP7579812B2 (ja) * 2019-05-31 2024-11-08 アイバイオ， インク． メソスケールペプチドを操作するための機械学習ベースの装置およびそのための方法およびシステム
WO2021119261A1 (en) * 2019-12-10 2021-06-17 Homodeus, Inc. Generative machine learning models for predicting functional protein sequences
MX2023005032A (es) * 2020-11-10 2023-05-16 Scripps Research Inst Anticuerpos para tratamientos con opioides.
WO2022119863A1 (en) * 2020-12-01 2022-06-09 Rubryc Therapeutics, Inc. Generalized scaffolds for polypeptide display and uses thereof
US20250179196A1 (en) * 2021-07-30 2025-06-05 Janssen Biotech, Inc. Materials and methods of making or using il-23r binding proteins
CN114384245B (zh) * 2022-03-24 2022-06-24 江苏美克医学技术有限公司 新型冠状病毒s-rbd蛋白和n蛋白双表位识别的联检试剂盒及其应用
WO2025235413A1 (en) * 2024-05-05 2025-11-13 Duke University Compositions targeting cancer antigens and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1279057C (zh) * 2002-07-12 2006-10-11 马菁 重组的抗cd25单克隆抗体、其编码序列及应用
US7438907B2 (en) 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
US8586709B2 (en) 2007-09-25 2013-11-19 Pastoral Greenhouse Research Limited Cell-permeabilising peptides and polypeptides for microbial cells
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
WO2014028776A1 (en) 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
EP2970398B1 (en) * 2013-03-13 2024-05-08 The United States of America, as Represented by The Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
EP2970486B1 (en) 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
EP3191121B1 (en) * 2014-09-10 2020-05-27 The University of Connecticut Identification of immunologically protective neo-epitopes for the treatment of cancers
US10377815B2 (en) 2015-05-05 2019-08-13 Albert Einstein College Of Medicine Bispecific antibodies and fusion proteins that bind to EBOV and NPC1
WO2018089829A1 (en) * 2016-11-10 2018-05-17 Fortis Therapeutics, Inc. Cd46-specific effector cells and uses thereof
US11879014B2 (en) * 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
EP3612565A4 (en) * 2017-04-18 2021-06-16 R-Pharm Overseas, Inc. ANTI-PD-L1 ANTIBODIES AND USES THEREOF
PE20210313A1 (es) * 2018-03-28 2021-02-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
EP3880227A4 (en) 2018-11-14 2022-11-09 RubrYc Therapeutics, Inc. ANTI-CD25 ANTIBODIES
JP7579812B2 (ja) 2019-05-31 2024-11-08 アイバイオ， インク． メソスケールペプチドを操作するための機械学習ベースの装置およびそのための方法およびシステム

Similar Documents

Publication Publication Date Title
JP2022513043A5 (https=)
JP7840836B2 (ja) 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
JP7323513B2 (ja) 抗４－１ｂｂ抗体とその作製及び使用方法
CN105849124B (zh) 双重特异性抗体
JP7257971B6 (ja) 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用
JP7604379B2 (ja) 抗ｐｄ－１抗体、その抗原結合フラグメントおよびそれらの医薬用途
JP5818804B2 (ja) ヒトｉｌ−２２ｒａに対するヒト化抗体
NZ717476A (en) Anti-garp protein and uses thereof
RU2018146050A (ru) Биспецифические связывающие белки, которые связывают иммуномодулирующий белок и опухолевый антиген
RU2015115956A (ru) Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения
JP6949012B2 (ja) Ｂ型肝炎表面抗原に対する抗体及びその使用
RU2011101969A (ru) Антитела к человеческому интерлейкину-20
JP2007530551A5 (https=)
JP2016509014A (ja) 新規の多特異的構成物
KR20160085793A (ko) Ｉｌ-17ａ 접합체 및 이의 용도
JP2016521272A (ja) インターロイキン−２０に対するヒト化抗体および炎症性疾患のための治療
JP6755513B2 (ja) 抗スクレロスチン抗体、その抗原結合フラグメントおよびその医薬用途
JP2019518473A5 (https=)
US12037409B2 (en) Antibody specifically bound to glycosylated CEACAM5
WO2013186630A2 (en) Humanized antibodies to ca215
CN120554509A (zh) 靶向CD3e/g的抗体或其抗原结合片段、其制备和应用
CN117843784A (zh) 抗人cd73抗体或其抗原结合片段及其应用
CN117866092A (zh) 抗人cd73抗体或其抗原结合片段及其应用
WO2025126102A1 (en) Enpp3 × cd3 bispecific antibodies and use thereof
WO2025256628A1 (zh) 抗adamts-7抗体及其应用